Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Presentation

Poster: ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease

Download PDF